Picture EBD Group Biotech Showcase 2024 San Francisco 650x100px

Document › Details

Immunicum AB. (12/29/17). "Press Release: Immunicum AB (publ) Announces the Outcome of the Rights Issue [Not for US, AU, CA, et al.]".

	Organisation	Immunicum AB (publ) (Nasdaq Stockholm: IMMU.ST)
	Today	Mendus AB (publ) (Nasdaq Stockholm: IMMU.ST)
	Group	Mendus (Group)
	Organisation 2	Nasdaq Stockholm
	Group	Nasdaq OMX (Group)
	Product	ilixadencel
	Product 2	investment banking
	Index term	Immunicum–SEVERAL: investment, 201711–201712 capital increase SEK200m net SEK168m with 25m new shares at SEK8/share
	Person	de Sousa, Carlos (Immunicum 201610– CEO before Zealand Pharma + Nycomed/Takeda + Pfizer + Novartis + BBB Therapeutics)
	Person 2	Schweitzer, Gretchen (Trophic Comunications 201801 before MacDougall European Office)

Original document
accessed by [iito] on 2018-10-16

Record changed: 2023-06-05

Picture EBD Group World of Partnering Opportunities 650x200px

More documents for Mendus (Group)

[1] Immunicum AB. (10/26/21). "Press Release: Immunicum Appoints Lotta Ferm as Chief Financial Officer"....
[2] Elicera Therapeutics AB. (3/22/21). "Press Release: Elicera Announces Appointment of ATMP Specialist Karin Hoogendoorn to the Board". Gothenburg....
[3] Immunicum AB. (11/18/20). "Press Release: Immunicum AB and DCprime Combine Forces to Establish Leader in Cell-Based Cancer Immunotherapies"....
[4] Glycotope GmbH. (9/21/20). "Press Release: DCprime and Glycotope Sign Licensing Agreement to Advance Program Combining Cancer Vaccination and Therapeutic Antibody Platforms". Leiden & Berlin....
[5] Immunicum AB. (12/13/19). "Press Release: Immunicum AB (publ) Announces Resignation of Carlos de Sousa as CEO"....
[6] Apceth Biopharma GmbH. (11/16/18). "Press Release: Apceth Biopharma GmbH Manufactures DCprime’s Cell-based Cancer Vaccine for Phase II Clinical Study". Munich....
[7] Immunicum AB. (10/16/18). "Press Release: Immunicum AB (publ) Raises SEK 351M in a Directed Issue and a Fully Guaranteed Rights Issue for Continued Clinical Development of Ilixadencel - a New and Innovative Cancer Immunotherapy [Not for US, AU, CA, et al...
[8] Immunicum AB. (10/16/18). "Press Release: Immunicum AB (publ) Clarifies Information Regarding Directed Issue [Not for US, AU, CA, et al.]"....
[9] Immunicum AB. (10/16/18). "Press Release: Notice of Extraordinary General Meeting in Immunicum AB (publ)"....
[10] Immunicum AB. (9/27/18). "Press Release: Immunicum AB (publ) Announces Upcoming Presentations at Conferences in October"....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]